Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Roivant Sciences
Deal Size : $200.0 million
Deal Type : Financing
Roivant Unveils Targeted Protein Degradation Platform
Details : Roivant Sciences has secured $200 million to advance its protein degradation ambitions. Armed with the money, Roivant CEO Vivek Ramaswamy plans to use the VantAI platform to spawn multiple new biotech startups.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Roivant Sciences
Deal Size : $200.0 million
Deal Type : Financing
Lead Product(s) : Porustobart
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Nona Biosciences
Deal Size : $75.0 million
Deal Type : Series B Financing
Harbour BioMed Raises $75 Million Series B+ Venture Capital
Details : More recently, the company has leveraged the power of its antibody discovery platform in select other areas of great unmet medical needs, such as in coronavirus disease (COVID-19).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
March 12, 2020
Lead Product(s) : Porustobart
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Nona Biosciences
Deal Size : $75.0 million
Deal Type : Series B Financing
Reset All
